PRORADIUM: Prospective analysis of the impact of germline mutations in homologous recombination (HR) genes on the response to radium-223 for metastatic castration resistant prostate cancer (mCRPC)

dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorCastro, E.
dc.contributor.authorLozano Mejorada, R.
dc.contributor.authorMedina, A.
dc.contributor.authorGiorgi, U.
dc.contributor.authorRomero Laorden, N.
dc.contributor.authorConteduca, V.
dc.contributor.authorDe Velasco, G.
dc.contributor.authorAlameda, D.
dc.contributor.authorSanz, A.
dc.contributor.authorPuente, J.
dc.contributor.authorGonzalez del Alba, A.
dc.contributor.authorBorrega, P.
dc.contributor.authorVilla Guzman, J. C.
dc.contributor.authorFernandez-Parra, E. M.
dc.contributor.authorRodriguez-Vida, A.
dc.contributor.authorChirivella, I.
dc.contributor.authorVazquez, F.
dc.contributor.authorMorales Barrera, R.
dc.contributor.authorLorente, D.
dc.contributor.authorOlmos, D.
dc.contributor.authoraffiliation[Castro, E.] Spanish Natl Canc Res Ctr, Prostate Canc Res Unit, Madrid, Spain
dc.contributor.authoraffiliation[Lozano Mejorada, R.] Spanish Natl Canc Res Ctr, Prostate Canc Res Unit, Madrid, Spain
dc.contributor.authoraffiliation[Sanz, A.] Spanish Natl Canc Res Ctr, Prostate Canc Res Unit, Madrid, Spain
dc.contributor.authoraffiliation[Olmos, D.] Spanish Natl Canc Res Ctr, Prostate Canc Res Unit, Madrid, Spain
dc.contributor.authoraffiliation[Medina, A.] Ctr Oncol Coruna, Med Oncol, La Coruna, Spain
dc.contributor.authoraffiliation[Giorgi, U.] IRCCS, Ist Romagnolo Studio Tumori, Dept Med Oncol, Meldola, Italy
dc.contributor.authoraffiliation[Conteduca, V.] IRCCS, Ist Romagnolo Studio Tumori, Dept Med Oncol, Meldola, Italy
dc.contributor.authoraffiliation[Romero Laorden, N.] Hosp Univ Princesa, Dept Oncol, Madrid, Spain
dc.contributor.authoraffiliation[De Velasco, G.] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Alameda, D.] Biomed Res Inst Malaga IBIMA, Genitourinary Oncol Traslat Res Grp, Malaga, Spain
dc.contributor.authoraffiliation[Puente, J.] Hosp Clin San Carlos, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Dept Med Oncol, CIBERONC, Madrid, Spain
dc.contributor.authoraffiliation[Gonzalez del Alba, A.] Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Borrega, P.] Hosp San Pedro Alcantara, Dept Med Oncol, Caceres, Spain
dc.contributor.authoraffiliation[Villa Guzman, J. C.] Hosp Gen Univ Ciudad Real, Dept Med Oncol, Ciudad Real, Spain
dc.contributor.authoraffiliation[Fernandez-Parra, E. M.] Hosp Virgen Valme, Dept Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Rodriguez-Vida, A.] Hosp Mar, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Chirivella, I.] INCLIVA Biomed Res Inst, Dept Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Vazquez, F.] Hosp Gen Univ Elche, Dept Med Oncol, Elche, Spain
dc.contributor.authoraffiliation[Morales Barrera, R.] Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Lorente, D.] Consorci Hosp Prov Castellon, Dept Med Oncol, Castellon de La Plana, Spain
dc.contributor.funderBayer
dc.date.accessioned2025-01-07T15:08:41Z
dc.date.available2025-01-07T15:08:41Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.1103
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.1103
dc.identifier.urihttps://hdl.handle.net/10668/26912
dc.identifier.wosID700527701054
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.organizationSAS - Hospital Universitario Virgen de Valme
dc.page.numberS638-S639
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titlePRORADIUM: Prospective analysis of the impact of germline mutations in homologous recombination (HR) genes on the response to radium-223 for metastatic castration resistant prostate cancer (mCRPC)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files